Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: The United States Food and Drug Administration (US FDA) had conducted a Pre-Approval Inspection (PAI) of the new injectable facility of Eugia Steriles (a 100% subsidiary of Eugia Pharma Specialities and a stepdown subsidiary of the Company), situated at Parawada Mandal, Anakapalli District, Andhra Pradesh, from March 28, 2024 to April 05, 2024. The Unit has now received the Establishment Inspection Report (EIR) and the inspection is closed.
The above information is a part of company’s filings submitted to BSE.
